Kras G12Dand p53 mutation cause primary intrahepatic cholangiocarcinoma

Cancer Research

Volumn 72, Issue 6, 2012, Pages 1557-1567

  O'Dell, Michael R ^a   Huang, Jing Li ^a   Whitney Miller, Christa L ^a   Deshpande, Vikram ^b   Rothberg, Paul ^a   Grose, Valerie ^a   Rossi, Randall M ^a   Zhu, Andrew X ^b   Land, Hartmut ^a   Bardeesy, Nabeel ^b   Hezel, Aram F ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; GENE ACTIVATION; GENE DELETION; GENE MUTATION; GENETIC ENGINEERING; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; LATENT PERIOD; METASTASIS; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIMARY INTRAHEPATIC CHOLANGIOCARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC ENGINEERING; HUMANS; LIVER NEOPLASMS; MICE; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863258898     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3596     Document Type: Article

References (49)

1. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2011;28:3531-40.
2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-25. (Pubitemid 38738341)
3. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2011;362:1273-81.
4. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Köckerling F, Hauss J, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000;47:721-7.
5. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706-12. (Pubitemid 36528874)
6. Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer 2011;11:60.
7. Tannapfel A, Weinans L, Geissler F, Schütz A, Katalinic A,Köckerling F, et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci 2000;45:317-24. (Pubitemid 30133893)
8. Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001;91:1332-41. (Pubitemid 32267045)
9. Wu TT, Levy M, Correa AM, Rosen CB, Abraham SC. Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases. Cancer 2009;115:4564-75.
10. Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 2006;44:1333-43. (Pubitemid 44748384)
11. Zen Y, Adsay NV, Bardadin K, Colombari R, Ferrell L, Haga H, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007;20:701-9. (Pubitemid 46788877)
12. Xu AM, Xian ZH, Zhang SH, Chen XF. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature. Eur J Gastroenterol Hepatol 2009;21:580-4.
13. Redston MS, Wanless IR. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected]. Mod Pathol 1996;9:233-7. (Pubitemid 26126548)
14. Kiguchi K, Carbajal S, Chan K, Beltrán L, Ruffino L, Shen J, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61:6971-6. (Pubitemid 32946479)
15. Elmore LW, Sirica AE. Phenotypic characterization of metaplastic intestinal glands and ductular hepatocytes in cholangiofibrotic lesions rapidly induced in the caudate liver lobe of rats treated with furan. Cancer Res 1991;51:5752-9.
16. Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, et al. erbB-2/ neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 2005;129:2047-57. (Pubitemid 41772979)
17. Sirica AE, Zhang Z, Lai GH, Asano T, Shen XN, Ward DJ, et al. A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 2008;47:1178-90. (Pubitemid 351547904)
18. Braun L, Goyette M, Yaswen P, Thompson NL, Fausto N. Growth in culture and tumorigenicity after transfection with the ras oncogene of liver epithelial cells from carcinogen-treated rats. Cancer Res 1987;47:4116-24. (Pubitemid 17108480)
19. Lin YZ, Brunt EM, Bowling W, Hafenrichter DG, Kennedy SC, Flye MW, et al. Ras-transduced diethylnitrosamine-treated hepatocytes develop into cancers of mixed phenotype in vivo. Cancer Res 1995;55:5242-50.
20. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinomain p53-deficient mice. Cancer Res 2006;66:6622-7. (Pubitemid 44085618)
21. Chen YW, Klimstra DS, Mongeau ME, Tatem JL, Boyartchuk V, Lewis BC. Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res 2007;67:7589-96. (Pubitemid 47281350)
22. Avruch J, Zhou D, Fitamant J, Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer 2011;104:24-32.
23. Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006;116:1843-52. (Pubitemid 44033309)
24. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54. (Pubitemid 44323701)
25. Tuveson D, Hanahan D. Translational medicine: Cancer lessons from mice to humans. Nature 2011;471:316-7.
26. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-8. (Pubitemid 34008190)
27. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25. (Pubitemid 34326692)
28. Postic C, Magnuson MA. DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 2000;26:149-50. (Pubitemid 30158104)
29. Duncan AW, Dorrell C, Grompe M. Stem cells and liver regeneration. Gastroenterology 2009;137:466-81.
30. Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008;47:1544-56. (Pubitemid 351702738)
31. Jain D, Sarode VR, Abdul-Karim FW, Homer R, Robert ME. Evidence for the neoplastic transformation of Von-Meyenburg complexes. Am J Surg Pathol 2000;24:1131-9. (Pubitemid 30612835)
32. Tannapfel A, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002;197:624-31.
33. Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090-8.
34. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46. (Pubitemid 38167315)
35. Engelman JA, Chen L, Tan X, Crosby K, Guirmaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
36. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011;29:2357-63.
37. McCormick F. Success and failure on the ras pathway. Cancer Biol Ther 2007;6:1654-9. (Pubitemid 351590340)
38. Yang S, Wang X, Contino G, Liesa M, Sahin E, Bause A, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011;25:717-29.
39. Guo JY, Chen HY, Mathew R, Fan J, Strokecker AM, Karsii-Uzunbas G, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011;25:460-70.
40. Lock R, Roy S, Kenific CM, Su JS, Salas S, Ronen SM, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011;22:165-78.
41. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev 2011;25:1999-2010.
42. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008;4:151-75. (Pubitemid 351231180)
43. Jarnagin WR, Weber S, Tickoo SK, Koca JB, Oblekwe S, Fong Y, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002;94:2040-6. (Pubitemid 34270058)
44. Woo HG, Lee JH, Yoon JH, Kinm CY, Lee HS, Jang JJ, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 2011;70:3034-41.
45. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k-ras-2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 2001;84:982-9. (Pubitemid 32385844)
46. Bardeesy N, Cheng KH, Berger JH, Chi GC, Pahler J, Olson P, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006;20:3130-46. (Pubitemid 44790628)
47. Hou YJ, Dong LW, Tan YX, Yang GZ, Pan YF, Li Z, et al. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma. Lab Invest 2011;91:1146-57.
48. Dong LW, Hou YJ, Tan YX, Pan YO, Wang M, Wang HY, et al. Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. Autophagy 2011;7:1222-9.
49. Bardeesy N, Aguirre AJ, Chu GC, Cehng KH, Lopez LV, Hezel AF, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 2006;103:5947-52.